This year marks ten years since the MHRA joined seven other global regulators to establish ICMRA to address the need for strong global cooperation and alignment in the regulation of medicinal products.
ICMRA's major achievement over the past decade has been the leadership of its membership working together throughout the COVID-19 pandemic. As the first member of ICMRA to approve the COVID-19 vaccine developed by Pfizer/BioNTech for use in the UK, the MHRA worked together with other members to expedite and streamline development and approval of COVID-19 vaccines and treatments and helped to increase the efficiency and effectiveness of regulatory processes and decision making.
Over the past ten years, as a founding member of ICMRA, we've demonstrated how international collaboration can address major health challenges around the world. In the coming years, the MHRA will continue to support ICMRA to address current and emerging human medicine regulatory and safety challenges, strengthen collaboration and communication and enhance the quality, safety and efficacy of medicines for the benefit of patients worldwide.